ArticleAmerican journal of translational research2026
The diagnostic value of targeted next-generation sequencing for smear-negative and sputum-scarce pulmonary tuberculosis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the diagnostic performance of targeted next-generation sequencing (tNGS) in pulmonary tuberculosis (PTB).
methodsThis retrospective study included 164 suspected PTB patients admitted to Anhui Chest Hospital between October 2022 and October 2024. All patients were smear-negative or sputum-scarce. Clinical specimens were tested simultaneously with tNGS, SAT-TB, GeneXpert MTB/RIF, and Mycobacterium tuberculosis (MTB) culture.
resultsAmong 108 diagnosed PTB patients, the sensitivity of tNGS was significantly superior to that of other methods. The negative predictive value (NPV) and accuracy of tNGS were 66.67% and 82.93%, which were superior to other methods. In bronchoalveolar lavage fluid (BALF) specimens, the positive detection rate of tNGS reached 48.12%, significantly higher than that of other methods (P<0.0001). In pleural effusion specimens, the positive detection rate of tNGS was 38.10%, which was significantly better than that of SAT-TB and GeneXpert MTB/RIF (P<0.01). ROC curve analysis showed that the AUC value of tNGS reached 0.87, significantly higher than that of the culture method, GeneXpert MTB/RIF, and SAT-TB. The combined detection strategy further increased the sensitivity to 79.63%, and the overall diagnostic accuracy reached 86.59%.
conclusionstNGS demonstrates superior diagnostic performance for tuberculosis diagnosis, particularly in alternative specimens such as BALF and pleural effusion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.